Curcumin Compounds with Their Effect on Metabolic-Associated Fatty Liver Disease (MAFLD) Biochemical Parameters

Authors

  • Erlita Kusuma Wardani University of Lampung
  • Evi Kurniawati
  • Oktadoni Saputra

DOI:

https://doi.org/10.53089/medula.v12i3.482

Keywords:

biochemistry, curcumin, liver, MAFLD

Abstract

Previously, the term Metabolic-Associated Fatty Liver Disease (MAFLD) was known as Non-Alcoholic Fatty Liver Disease (NAFLD). This disorder is characterized by excessive accumulation of fat in hepatocytes. MAFLD is a significant public health problem, where liver disease is chronic and common worldwide. Non-pharmacological therapy is recommended to support pharmacological treatments, such as diet, physical activity, or supplementation. Curcumin compound is one part of non-pharmacological therapy which is included in supplementation. Curcumin supplementation has been shown to have many health-promoting benefits, such as antioxidant, anti-inflammatory, and anticancer effects. Therefore, the authors explored various literature sources to analyze scientific publications related to the effect of curcumin supplementation on the biochemical parameters of MAFLD. Several studies have shown that curcumin has a clear potential for the treatment of MAFLD. However, further research is still needed.

References

Pavlides, M.; Cobbold, J. Non-alcoholic fatty liver disease. Medicine 2019, 47, 728–733.

Welsh, J.A.; Karpen, S.; Vos, M.B. Increasing Prevalence of Nonalcoholic Fatty Liver Disease Among United States Adolescents, 1988–1994 to 2007–2010. J. Pediatr. 2013, 162, 496–500.e1.

Kumar, R.; Priyadarshi, R.N.; Anand, U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J. Clin. Transl. Hepatol. 2020, 8, 76–86.

Słomko, J.; Zalewska, M.; Niemiro, W.; Kujawski, S.; Słupski, M.; Januszko-Giergielewicz, B.; Zawadka-Kunikowska, M.; Newton, J.; Hodges, L.; Kubica, J.; et al. Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. J. Clin. Med. 2021, 10, 1659. [CrossRef]

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388–1402.

Hewlings, S.; Kalman, D. Curcumin: A Review of Its’ Effects on Human Health. Foods 2017, 6, 92.

Rahmani, S.; Asgary, S.; Askari, G.; Keshvari, M.; Hatamipour, M.; Feizi, A.; Sahebkar, A. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother. Res. PTR 2016, 30, 1540–1548. [CrossRef]

Moradi Kelardeh, B.; Keshavarz, S.; Karimi, M. Effects of Nonlinear Resistance Training with Curcumin Supplement on Liver Enzymes in Men with Non- Alcoholic Fatty Liver Disease. Rep. Health Care 2017, 3, 1–9.

Ghaffari, A.; Rafraf, M.; Navekar, R.; Sepehri, B.; Asghari-Jafarabadi, M.; Ghavami, S.-M. Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD). Int. J. Vitam. Nutr. Res. 2019, 89, 293–302.

Chashmniam, S.; Mirhafez, S.R.; Dehabeh, M.; Hariri, M.; Azimi Nezhad, M.; Nobakht M Gh, B.F. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Eur. J. Clin. Nutr. 2019, 73, 1224–1235. [CrossRef]

Mirhafez, S.R.; Farimani, A.R.; Dehhabe, M.; Bidkhori, M.; Hariri, M.; Ghouchani, F.N.M.; Abdollahi, F. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J. Gastrointest. Liver Dis. 2019, 28, 7. [CrossRef] [PubMed]

Panahi, Y.; Kianpour, P.; Mohtashami, R.; Soflaei, S.S.; Sahebkar, A. Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: A clinical study. J. Asian Nat. Prod. Res. 2019, 21, 798–805. [CrossRef] [PubMed]

Hariri, M. A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease_ A randomized, double-blind, placebo-controlled, clinical trial. Complement. Ther. Med. 2020, 6, 102447.

Moradi Kelardeh, B.; Rahmati-Ahmadabad, S.; Farzanegi, P.; Helalizadeh, M.; Azarbayjani, M.-A. Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease. J. Bodyw. Mov. Ther. 2020, 24, 154–160.

Saberi-Karimian, M.; Keshvari, M.; Ghayour-Mobarhan, M.; Salehizadeh, L.; Rahmani, S.; Behnam, B.; Jamialahmadi, T.; Asgary, S.; Sahebkar, A. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Complement. Ther. Med. 2020, 49, 102322.

Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016, 65, 1038–1048.

Pulido-Moran, M.; Moreno-Fernandez, J.; Ramirez-Tortosa, C.; Ramirez-Tortosa, M. Curcumin and Health. Molecules 2016, 21, 264.

Farzaei, M.H.; Zobeiri, M.; Parvizi, F.; El-Senduny, F.F.; Marmouzi, I.; Coy-Barrera, E.; Naseri, R.; Nabavi, S.M.; Rahimi, R.; Abdollahi, M. Curcumin in Liver Diseases: A Systematic Review of the Cellular Mechanisms of Oxidative Stress and Clinical Perspective. Nutrients 2018, 10, 855.

Przybylska, S. Kurkumina—prozdrowotny barwnik kurkumy. Probl. Hig. Epidemiol. 2015, 96, 414–420.

Gorabi, A.M.; Razi, B.; Aslani, S.; Abbasifard, M.; Imani, D.; Sathyapalan, T.; Sahebkar, A. Effect of curcumin on proinflammatory cytokines: A meta-analysis of randomized controlled trials. Cytokine 2021, 143, 155541.

Maciejewska, D.; Stachowska, E. Niealkoholowe stłuszczenie wa˛troby (NAFLD)—epidemia XXI wieku. Postepy Hig. Dosw. 2018, 72, 659–670.

Chuengsamarn, S.; Rattanamongkolgul, S.; Luechapudiporn, R.; Phisalaphong, C.; Jirawatnotai, S. Curcumin Extract for Prevention of Type 2 Diabetes. Diabetes Care 2012, 35, 2121–2127.

Ismail, N.A.; Ragab, S.; El-Baky, A.N.E.A.; Hamed, M.; Ibrahim, A.A. Effect of oral curcumin administration on insulin resistance, serum resistin and fetuin-A in obese children: Randomized placebo-controlled study. Res. J. Pharm. Biol. Chem. Sci. 2014, 5, 887–896.

Panahi, Y.; Kianpour, P.; Mohtashami, R.; Jafari, R.; Simental-Mendía, L.E.; Sahebkar, A. Curcumin Lowers Serum Lipids and Uric Acid in SubjectsWith Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. J. Cardiovasc. Pharmacol. 2016, 68, 223–229.

Gupta, S.C.; Patchva, S.; Aggarwal, B.B. Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. AAPS J. 2013, 15, 195–218. [CrossRef] [PubMed]

Noorafshan, A.; Ashkani-Esfahani, S. A Review of Therapeutic Effects of Curcumin. Curr. Pharm. Des. 2013, 19, 2032–2046

Published

2023-01-19

How to Cite

Erlita Kusuma Wardani, Evi Kurniawati, & Oktadoni Saputra. (2023). Curcumin Compounds with Their Effect on Metabolic-Associated Fatty Liver Disease (MAFLD) Biochemical Parameters. Medical Profession Journal of Lampung, 12(3), 568-574. https://doi.org/10.53089/medula.v12i3.482

Issue

Section

Artikel